SNDX SYNDAX PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - FDA Approval Syndax Pharmaceuticals announced FDA approval for Revuforj, the first menin inhibitor for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged one year and older, and will hold a conference call regarding this announcement.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC